MeSH term
Frequency | Condition_Probility | Diagnosis, Differential | 3 | 0.0 |
Humans | 299 | 0.0 |
Male | 90 | 0.0 |
Middle Aged | 107 | 0.0 |
English Abstract | 12 | 0.0 |
Microsatellite Repeats | 22 | 1.0 |
Mutation | 13 | 0.0 |
*Acid Anhydride Hydrolases | 203 | 87.0 |
*Apoptosis | 7 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Comparative Study | 24 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Immunohistochemistry | 78 | 0.0 |
Neoplasm Proteins/deficiency/genetics/*physiology | 2 | 40.0 |
Neoplasm Staging | 37 | 1.0 |
Paraffin Embedding | 2 | 0.0 |
Prognosis | 30 | 0.0 |
Research Support, Non-U.S. Gov't | 199 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 19 | 0.0 |
Retrospective Studies | 8 | 0.0 |
Survival Analysis | 12 | 0.0 |
Aged | 73 | 0.0 |
Aged, 80 and over | 40 | 0.0 |
*Chromosomes, Human, Pair 3 | 24 | 6.0 |
Female | 146 | 0.0 |
*Genes, Tumor Suppressor | 33 | 3.0 |
Loss of Heterozygosity/genetics | 5 | 3.0 |
Microsatellite Repeats/genetics | 7 | 1.0 |
Neoplasm Proteins/*genetics | 53 | 5.0 |
Animals | 50 | 0.0 |
Cell Line | 3 | 0.0 |
Mice | 35 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 90 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Chromosome Fragile Sites | 20 | 14.0 |
Chromosome Fragility/*genetics | 5 | 29.0 |
Exons/genetics | 4 | 0.0 |
Genetic Markers/genetics | 4 | 0.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Alleles | 13 | 0.0 |
Chromosome Aberrations | 8 | 1.0 |
Chromosome Deletion | 8 | 1.0 |
Chromosomes, Human, Pair 3/genetics | 14 | 10.0 |
DNA Mutational Analysis | 12 | 0.0 |
DNA, Neoplasm/analysis | 14 | 1.0 |
Genes, Tumor Suppressor | 36 | 4.0 |
Loss of Heterozygosity | 30 | 3.0 |
Polymerase Chain Reaction | 46 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 44 | 0.0 |
Adult | 73 | 0.0 |
Neoplasm Proteins/*analysis | 10 | 3.0 |
Survival Rate | 13 | 0.0 |
Tumor Markers, Biological/*analysis | 6 | 0.0 |
Base Sequence | 30 | 0.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
DNA, Neoplasm/genetics | 6 | 0.0 |
Gene Expression | 21 | 0.0 |
Genetic Markers | 11 | 0.0 |
*Loss of Heterozygosity | 31 | 8.0 |
Lymphatic Metastasis | 13 | 1.0 |
Microsatellite Repeats/*genetics | 4 | 1.0 |
Molecular Sequence Data | 32 | 0.0 |
Neoplasm Proteins/analysis/*genetics | 5 | 16.0 |
Polymorphism, Genetic | 4 | 0.0 |
RNA, Messenger/genetics | 6 | 0.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Binding Sites | 5 | 0.0 |
Dinucleoside Phosphates/chemistry | 2 | 50.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Adenoviridae/genetics | 6 | 1.0 |
Caspases/metabolism | 2 | 0.0 |
Cell Cycle | 3 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Gene Therapy/methods | 2 | 2.0 |
Mice, Nude | 13 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 12 | 6.0 |
Transduction, Genetic | 4 | 1.0 |
Transgenes/genetics | 2 | 2.0 |
Tumor Cells, Cultured | 56 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 10 | 5.0 |
Cluster Analysis | 2 | 1.0 |
DNA, Neoplasm/*genetics | 4 | 1.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Mouth Neoplasms/*genetics | 5 | 10.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
RNA, Messenger/analysis | 6 | 0.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Alternative Splicing | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 21 | 0.0 |
Transcription, Genetic | 20 | 0.0 |
Adenocarcinoma/*genetics | 5 | 3.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
Gene Deletion | 21 | 1.0 |
Lung Neoplasms/*genetics | 6 | 2.0 |
Case-Control Studies | 4 | 0.0 |
DNA/analysis | 2 | 0.0 |
Methylation | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 10 | 0.0 |
Promoter Regions (Genetics) | 8 | 0.0 |
Risk Factors | 5 | 0.0 |
Smoking/adverse effects | 3 | 1.0 |
Chromosomes, Human, Pair 3 | 17 | 8.0 |
Down-Regulation | 6 | 0.0 |
Esophageal Neoplasms/*genetics/metabolism/pathology | 2 | 25.0 |
Neoplasm Proteins/biosynthesis/*genetics | 6 | 6.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
Acid Anhydride Hydrolases/genetics/*metabolism | 3 | 100.0 |
Cell Line, Tumor | 10 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Kinetics | 4 | 0.0 |
Transfection | 9 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Neoplasm Proteins/genetics | 21 | 4.0 |
*Tumor Suppressor Proteins | 6 | 0.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Asbestos/*adverse effects | 2 | 14.0 |
Carcinoma, Non-Small-Cell Lung/genetics/pathology | 2 | 20.0 |
*Gene Expression Regulation, Neoplastic | 18 | 1.0 |
Loss of Heterozygosity/*genetics | 6 | 6.0 |
Lung Neoplasms/*genetics/pathology | 6 | 6.0 |
Smoking/*adverse effects | 4 | 1.0 |
*Gene Deletion | 15 | 1.0 |
*Genes, p16 | 2 | 2.0 |
*Mutation | 8 | 0.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Proto-Oncogene Proteins/genetics/metabolism | 2 | 1.0 |
Dinucleoside Phosphates/metabolism | 5 | 20.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Immunoblotting | 5 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Lung/metabolism | 2 | 1.0 |
Neoplasm Proteins/*biosynthesis | 7 | 7.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Rats | 4 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cell Division | 7 | 0.0 |
Chromosome Mapping | 22 | 0.0 |
Disease-Free Survival | 5 | 0.0 |
Neoplasm Invasiveness | 13 | 1.0 |
Time Factors | 9 | 0.0 |
*DNA Methylation | 12 | 1.0 |
Multivariate Analysis | 6 | 0.0 |
Evaluation Studies | 2 | 0.0 |
*Gene Therapy | 4 | 1.0 |
Neoplasm Proteins/*genetics/metabolism | 11 | 7.0 |
Adenocarcinoma/genetics | 3 | 4.0 |
Chromosome Breakage | 3 | 3.0 |
Homozygote | 5 | 0.0 |
Precancerous Conditions/genetics | 3 | 14.0 |
Pulmonary Fibrosis/*genetics | 2 | 28.0 |
Carcinoma, Squamous Cell/*genetics/metabolism | 2 | 7.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Neoplasm Proteins/*biosynthesis/genetics | 10 | 6.0 |
Precancerous Conditions/*metabolism/pathology | 2 | 9.0 |
DNA Repair/*genetics | 3 | 0.0 |
DNA-Binding Proteins/genetics | 5 | 0.0 |
Lasers | 2 | 1.0 |
Lung Neoplasms/etiology/*genetics | 2 | 7.0 |
Apoptosis/genetics | 4 | 1.0 |
Cell Division/genetics | 6 | 1.0 |
Chromosome Fragility/genetics | 2 | 40.0 |
Acid Anhydride Hydrolases/*genetics | 9 | 75.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/metabolism | 2 | 25.0 |
CpG Islands/*genetics | 3 | 3.0 |
DNA Methylation | 6 | 0.0 |
Gene Silencing | 5 | 1.0 |
Lung Neoplasms/*genetics/metabolism | 2 | 5.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Adenocarcinoma/*genetics/metabolism | 2 | 5.0 |
Exons | 7 | 0.0 |
RNA Splicing/*genetics | 3 | 3.0 |
RNA, Neoplasm/genetics/metabolism | 3 | 2.0 |
Stomach Neoplasms/*genetics/metabolism | 2 | 7.0 |
Disease Progression | 15 | 0.0 |
Genes, p53 | 3 | 0.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Breast Neoplasms/*genetics | 6 | 0.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Blotting, Western | 11 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Lymphocytes/metabolism | 3 | 1.0 |
*Protein Biosynthesis | 15 | 3.0 |
Proteins/genetics/*metabolism | 10 | 2.0 |
Cervix Neoplasms/*genetics | 4 | 14.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
*Neoplasm Proteins | 70 | 9.0 |
Protein Biosynthesis | 17 | 1.0 |
Proteins/*genetics | 72 | 4.0 |
Disease Models, Animal | 2 | 0.0 |
Genes, Tumor Suppressor/genetics | 5 | 3.0 |
Cervix Neoplasms/*genetics/metabolism | 2 | 18.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
Carcinoma, Small Cell/*genetics/pathology | 2 | 9.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Blotting, Southern | 6 | 0.0 |
DNA Primers | 8 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Genes, Tumor Suppressor/*genetics | 6 | 1.0 |
Breast Neoplasms/*genetics/*pathology | 2 | 3.0 |
Mice, SCID | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Models, Biological | 2 | 0.0 |
Neoplasms, Experimental | 2 | 5.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
Chromosomes, Human, Pair 3/*genetics | 15 | 7.0 |
Cohort Studies | 3 | 0.0 |
Polymerase Chain Reaction/methods | 8 | 0.0 |
Apoptosis/*genetics | 4 | 1.0 |
DNA Fragmentation | 2 | 0.0 |
Gene Therapy | 2 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
Carcinoma, Renal Cell/*genetics/pathology | 3 | 8.0 |
Kidney Neoplasms/*genetics/pathology | 2 | 2.0 |
Adolescent | 7 | 0.0 |
Ki-67 Antigen/analysis | 3 | 1.0 |
Lung Neoplasms/*genetics/mortality/pathology | 2 | 18.0 |
Acid Anhydride Hydrolases/*biosynthesis/genetics | 2 | 100.0 |
Point Mutation | 5 | 0.0 |
Proteins/*genetics/metabolism | 11 | 4.0 |
Sequence Deletion | 6 | 0.0 |
Carcinoma, Squamous Cell/genetics/*metabolism/pathology | 3 | 12.0 |
Cervix Neoplasms/genetics/*metabolism/pathology | 2 | 28.0 |
Proportional Hazards Models | 3 | 0.0 |
Proteins/genetics | 12 | 1.0 |
Genes, Tumor Suppressor/*physiology | 5 | 4.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
Azacitidine/*analogs & derivatives/pharmacology | 2 | 2.0 |
Blotting, Northern | 4 | 0.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 2 | 3.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/metabolism/pathology | 2 | 18.0 |
Lung Neoplasms/*genetics/metabolism/pathology | 2 | 9.0 |
*Chromosome Fragility | 16 | 13.0 |
DNA Damage | 3 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Receptors, Retinoic Acid/genetics | 2 | 2.0 |
Neoplasm Metastasis | 5 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Hela Cells | 5 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Cattle | 3 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Esophageal Neoplasms/*genetics | 6 | 8.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Genes, p53/*genetics | 3 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Ploidies | 2 | 0.0 |
Protein p53/metabolism | 5 | 0.0 |
*Gene Expression | 4 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Genes, p53/genetics | 2 | 0.0 |
Genes, ras/genetics | 2 | 1.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Protein Binding | 2 | 0.0 |
Adenoma/*metabolism | 3 | 5.0 |
Apoptosis | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Colorectal Neoplasms/*metabolism | 4 | 9.0 |
*Hydrolases | 5 | 62.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
*Sequence Deletion | 3 | 0.0 |
Base Pair Mismatch/genetics | 2 | 4.0 |
DNA Repair | 5 | 0.0 |
Protein p53/biosynthesis/genetics | 2 | 4.0 |
Proteins/*metabolism | 4 | 0.0 |
BRCA2 Protein | 3 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Carcinoma, Squamous Cell/genetics | 2 | 3.0 |
Esophageal Neoplasms/*genetics/pathology | 2 | 6.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Chi-Square Distribution | 3 | 0.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Histidine/genetics | 4 | 7.0 |
Trinucleotide Repeat Expansion | 2 | 5.0 |
Neoplasm Proteins/biosynthesis | 3 | 3.0 |
Treatment Outcome | 2 | 0.0 |
Carcinoma, Renal Cell/*genetics | 5 | 5.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Kidney Neoplasms/*genetics | 4 | 1.0 |
Neoplasm Transplantation | 4 | 0.0 |
Proteins/*genetics/*metabolism | 2 | 2.0 |
Dinucleoside Phosphates/*metabolism | 4 | 19.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Proteins/*analysis/*genetics | 2 | 33.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Mutation/genetics | 3 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
China | 2 | 0.0 |
Tumor Markers, Biological/analysis | 4 | 0.0 |
Carcinoma in Situ/genetics | 2 | 10.0 |
Epithelium/pathology | 2 | 1.0 |
Hyperplasia | 3 | 0.0 |
Neoplasm Proteins/*analysis/genetics | 3 | 6.0 |
Proteins/*analysis/genetics | 2 | 8.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Carcinoma/*metabolism | 3 | 3.0 |
Barrett Esophagus/*genetics | 2 | 25.0 |
Precancerous Conditions/*genetics | 4 | 14.0 |
Hydrolysis | 5 | 0.0 |
Substrate Specificity | 7 | 0.0 |
Proteins/*analysis | 3 | 2.0 |
Phosphoric Monoester Hydrolases/*genetics | 2 | 0.0 |
Reference Values | 4 | 0.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
*Transcription, Genetic | 4 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Biological Markers | 2 | 0.0 |
Adenoma, Oxyphilic/classification/metabolism/pathology | 2 | 100.0 |
Carcinoma, Renal Cell/classification/metabolism/pathology | 2 | 100.0 |
Kidney Neoplasms/classification/*metabolism/*pathology | 2 | 100.0 |
Neoplasm Proteins/*metabolism | 12 | 2.0 |
Rabbits | 2 | 0.0 |
Neoplasm Proteins/*biosynthesis/*genetics | 2 | 20.0 |
Models, Molecular | 4 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
DNA, Viral/*analysis | 2 | 2.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Acid Anhydride Hydrolases/metabolism | 2 | 66.0 |
Stomach Neoplasms/*genetics/mortality/pathology | 2 | 33.0 |
Acid Anhydride Hydrolases/*metabolism | 5 | 100.0 |
Catalysis | 2 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Escherichia coli/genetics | 3 | 0.0 |
Neoplasm Proteins/*chemistry | 2 | 15.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
RNA, Neoplasm/isolation & purification | 2 | 6.0 |
*Genetic Markers | 2 | 0.0 |
Neoplasms/*genetics | 7 | 2.0 |
Translocation, Genetic | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Leukemia/*genetics/metabolism | 2 | 22.0 |
Acid Anhydride Hydrolases/*genetics/metabolism | 2 | 66.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Carcinoma, Non-Small-Cell Lung/genetics | 2 | 10.0 |
Chromosome Fragility | 7 | 12.0 |
Lung Neoplasms/genetics | 4 | 6.0 |
Cell Line, Transformed | 4 | 0.0 |
RNA, Neoplasm/metabolism | 3 | 3.0 |
Protein Conformation | 3 | 0.0 |
Proteins/*chemistry/genetics/metabolism | 3 | 30.0 |
Stereoisomerism | 2 | 0.0 |
*Chromosome Deletion | 3 | 0.0 |
Leukemia/*genetics | 3 | 2.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Acute Disease | 2 | 0.0 |
Child | 3 | 0.0 |
Smoking/metabolism | 2 | 3.0 |
Chromosome Disorders | 2 | 0.0 |
Protein p16/genetics | 4 | 4.0 |
Trans-Activators/genetics | 4 | 1.0 |
Child, Preschool | 2 | 0.0 |
Cytoskeletal Proteins/genetics | 2 | 3.0 |
Head and Neck Neoplasms/*genetics | 2 | 2.0 |
Proteins/analysis/*genetics | 2 | 6.0 |
Carcinoma, Small Cell/chemistry/*genetics | 2 | 100.0 |
Acid Anhydride Hydrolases/genetics | 3 | 42.0 |
Cadherins/genetics | 4 | 7.0 |
Cell Cycle Proteins/genetics | 3 | 3.0 |
Glutathione Transferase/genetics | 2 | 0.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 2 | 7.0 |
Tumor Suppressor Proteins/genetics | 2 | 2.0 |
p14ARF Protein/genetics | 2 | 9.0 |
Gene Expression Profiling | 3 | 0.0 |
Taiwan | 2 | 1.0 |
Up-Regulation | 2 | 0.0 |
Carcinoma/*genetics/metabolism | 3 | 10.0 |
*Translocation, Genetic | 2 | 0.0 |
Acid Anhydride Hydrolases/*analysis | 2 | 100.0 |
Epithelium/chemistry | 2 | 1.0 |
Genes, ras | 2 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Dimerization | 3 | 0.0 |
Ligands | 2 | 0.0 |
Acid Anhydride Hydrolases | 5 | 83.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Carcinoma, Small Cell/genetics | 2 | 5.0 |
Ovarian Neoplasms/genetics | 2 | 1.0 |
Pancreatic Neoplasms/genetics | 2 | 5.0 |
Sequence Tagged Sites | 2 | 0.0 |
Phenotype | 3 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 3 | 10.0 |
B-Lymphocytes | 2 | 1.0 |
Leukemia, Lymphocytic, Chronic/genetics | 2 | 28.0 |
Heterozygote | 5 | 0.0 |
Chromosomes, Human, Pair 3/*ultrastructure | 2 | 25.0 |
Conserved Sequence | 2 | 0.0 |
*Homozygote | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
*Helicobacter pylori | 2 | 1.0 |
Chromosome Fragile Sites/*genetics | 2 | 33.0 |
Base Pair Mismatch | 3 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
CpG Islands | 4 | 1.0 |
Ki-67 Antigen/metabolism | 3 | 1.0 |
Lung Neoplasms/genetics/*metabolism/pathology | 2 | 7.0 |
Genes, p16 | 3 | 3.0 |
Smoking | 2 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Papillomavirus Infections/complications | 2 | 40.0 |
Papillomavirus, Human/pathogenicity | 2 | 28.0 |
Reproducibility of Results | 3 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Protein p53/genetics | 3 | 1.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Intestinal Mucosa/metabolism | 2 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Embryo/anatomy & histology/*physiology | 2 | 22.0 |
Tumor Virus Infections/complications | 3 | 14.0 |
*Microsatellite Repeats | 3 | 1.0 |
Papovaviridae Infections/complications | 2 | 15.0 |
Genes, myc/*genetics | 2 | 2.0 |
